SMART-MS - Mesenchymal stem cells as regenerative treatment in multiple sclerosis
Neurological disorders are the leading cause of disability worldwide. Despite their high prevalence and socioeconomic burden, there is still no treatment available to directly promote repair of damage to the central nervous system (CNS) and thereby reverse neurological disability. A frequent cause of CNS injury and neurological disability in young adults is multiple sclerosis (MS).
Mesenchymal stem cells (MSCs) have the potential to induce CNS repair through multiple neuroregenerative mechanisms, including remyelination, immunomodulation and stimulation of endogenous neural stem cells.
The SMART-MS study aims to investigate the neuroregenerative potential of treatment with MSCs in MS and to increase the understanding of the underlying mechanisms of action.
ABOUT THE SPEAKER
Dr. Christopher Elnan Kvistad is a researcher at Neuro-Sysmed and a senior consultant in Neurology at Haukeland University Hospital. He is one of the principal investigators in the SMART-MS clinical trial.